AJANTPHARM IN EQUITY
loading…—
Day range—
52-week range—
Market cap—
P/E · TTM—
As of—
| ₹ CR · FY | FY22 | FY23 | FY24 | FY25 | FY26 | Sep'26 | YOY |
|---|---|---|---|---|---|---|---|
| Profit & loss | |||||||
| Revenue | 3,341 | 3,743 | 4,209 | 4,648 | 5,453 | — | — |
| Operating profit | 933 | 808 | 1,172 | 1,269 | 1,500 | — | — |
| OPM % | 27.9% | 21.6% | 27.8% | 27.3% | 27.5% | — | |
| Interest | 10 | 6 | 7 | 21 | 16 | — | — |
| Profit before tax | 909 | 745 | 1,114 | 1,189 | 1,378 | — | — |
| Net profit | 713 | 588 | 816 | 920 | 1,056 | — | — |
| NPM % | 21.3% | 15.7% | 19.4% | 19.8% | 19.4% | — | |
| Balance sheet & cash | |||||||
| Total assets | 4,000 | 4,582 | 4,530 | 4,904 | 6,037 | 6,425 | +6.4% |
| Equity | 3,264 | 3,388 | 3,567 | 3,790 | 4,527 | 4,858 | +7.3% |
| Debt | 25 | 36 | 35 | 47 | 260 | 154 | −40.8% |
| Cash from ops | 562 | 792 | 785 | 1,157 | 529 | — | — |
| Capex | — | — | — | — | — | — | — |
| CHECK | RESULT | VALUE |
|---|---|---|
| Net profit positive | n/a | — |
| Operating cash flow positive | n/a | — |
| ROA improved | n/a | 17.5% → — |
| Cash from ops > net profit | n/a | — |
| Leverage fell | ✓ PASS | 0.04 → 0.02 |
| Current ratio improved | n/a | — → — |
| Gross margin improved | n/a | 27.5% → — |
| Asset turnover improved | n/a | 0.9 → — |
| Interest cover above 3× | n/a | — |
| ₹ CR · QUARTER | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | YOY |
|---|---|---|---|---|---|---|---|---|---|
| Profit & loss | |||||||||
| Revenue | 1,146 | 1,170 | 1,303 | 1,354 | 1,375 | 1,422 | 1,626 | 1,794 | +32.5% |
| Operating profit | 321 | 297 | 351 | 328 | 382 | 333 | 424 | 548 | +67.1% |
| OPM % | 28.0% | 25.4% | 26.9% | 24.2% | 27.8% | 23.4% | 26.1% | 30.5% | |
| Interest | 8 | 6 | 5 | 3 | 5 | 2 | 3 | 2 | −33.3% |
| Profit before tax | 307 | 269 | 331 | 341 | 359 | 347 | 447 | 535 | +56.9% |
| Net profit | 233 | 225 | 255 | 260 | 274 | 267 | 334 | 388 | +49.2% |
| NPM % | 20.3% | 19.2% | 19.6% | 19.2% | 19.9% | 18.8% | 20.5% | 21.6% |